{"id": "article-120320_0", "title": "Pharmacologic Therapy for Obesity -- Continuing Education Activity", "content": "Obesity, a metabolic disease characterized by excessive adipose tissue, is a global epidemic affecting individuals of all ages. Classified by body mass index (BMI), it poses significant health risks, including diabetes, hypertension, hyperlipidemia, arthritis, sleep apnea, and cancer. Given its chronic nature and associated morbidity and mortality, prompt diagnosis and treatment are essential.", "contents": "Pharmacologic Therapy for Obesity -- Continuing Education Activity. Obesity, a metabolic disease characterized by excessive adipose tissue, is a global epidemic affecting individuals of all ages. Classified by body mass index (BMI), it poses significant health risks, including diabetes, hypertension, hyperlipidemia, arthritis, sleep apnea, and cancer. Given its chronic nature and associated morbidity and mortality, prompt diagnosis and treatment are essential."}
{"id": "article-120320_1", "title": "Pharmacologic Therapy for Obesity -- Continuing Education Activity", "content": "This activity will cover updates on recent advancements in pharmacologic therapies, focusing on their efficacy not only in weight loss but also in managing diabetes and improving cardiovascular health. The interprofessional approach to evaluating and treating obesity will be highlighted, emphasizing the importance of lifestyle modifications, medication, and, when necessary, bariatric surgery. Overall, clinicians will acquire valuable insights into the latest strategies for addressing obesity and its related health issues, enabling them to enhance patient care and outcomes.", "contents": "Pharmacologic Therapy for Obesity -- Continuing Education Activity. This activity will cover updates on recent advancements in pharmacologic therapies, focusing on their efficacy not only in weight loss but also in managing diabetes and improving cardiovascular health. The interprofessional approach to evaluating and treating obesity will be highlighted, emphasizing the importance of lifestyle modifications, medication, and, when necessary, bariatric surgery. Overall, clinicians will acquire valuable insights into the latest strategies for addressing obesity and its related health issues, enabling them to enhance patient care and outcomes."}
{"id": "article-120320_2", "title": "Pharmacologic Therapy for Obesity -- Continuing Education Activity", "content": "Objectives: Identify individuals at risk for obesity-related complications based on comprehensive assessments of BMI, medical history, and associated comorbidities. Screen patients for suitability and eligibility for pharmacologic treatment, considering contraindications, previous medical history, and risk factors. Implement evidence-based pharmacologic interventions as part of a multidisciplinary approach to manage obesity, integrating medications into a comprehensive treatment plan. Coordinate long-term care plans, ensuring continuity and addressing challenges related to weight maintenance and potential side effects of pharmacologic interventions. Access free multiple choice questions on this topic.", "contents": "Pharmacologic Therapy for Obesity -- Continuing Education Activity. Objectives: Identify individuals at risk for obesity-related complications based on comprehensive assessments of BMI, medical history, and associated comorbidities. Screen patients for suitability and eligibility for pharmacologic treatment, considering contraindications, previous medical history, and risk factors. Implement evidence-based pharmacologic interventions as part of a multidisciplinary approach to manage obesity, integrating medications into a comprehensive treatment plan. Coordinate long-term care plans, ensuring continuity and addressing challenges related to weight maintenance and potential side effects of pharmacologic interventions. Access free multiple choice questions on this topic."}
{"id": "article-120320_3", "title": "Pharmacologic Therapy for Obesity -- Introduction", "content": "Obesity is a pervasive chronic disease\u00a0that continues to rise\u00a0in prevalence globally,\u00a0affecting not\u00a0just\u00a0adults but also adolescents and children. It has reached epidemic proportions and is now recognized as a significant health crisis. [1]", "contents": "Pharmacologic Therapy for Obesity -- Introduction. Obesity is a pervasive chronic disease\u00a0that continues to rise\u00a0in prevalence globally,\u00a0affecting not\u00a0just\u00a0adults but also adolescents and children. It has reached epidemic proportions and is now recognized as a significant health crisis. [1]"}
{"id": "article-120320_4", "title": "Pharmacologic Therapy for Obesity -- Introduction", "content": "Epidemiological studies have defined obesity using the body mass index (BMI), calculated by dividing a person's weight in kilograms by the square of their height in meters.\u00a0This method\u00a0enables the\u00a0stratification of obesity-related health risks\u00a0within populations. A\u00a0BMI exceeding\u00a030 kg/m\u00b2 is considered diagnostic for obesity and is further subclassified into class 1 (30\u00a0to 34.9 kg/m\u00b2), class 2 (35\u00a0to 39.9 kg/m\u00b2), and class\u00a03, known as morbid obesity (\u226540 kg/m\u00b2).", "contents": "Pharmacologic Therapy for Obesity -- Introduction. Epidemiological studies have defined obesity using the body mass index (BMI), calculated by dividing a person's weight in kilograms by the square of their height in meters.\u00a0This method\u00a0enables the\u00a0stratification of obesity-related health risks\u00a0within populations. A\u00a0BMI exceeding\u00a030 kg/m\u00b2 is considered diagnostic for obesity and is further subclassified into class 1 (30\u00a0to 34.9 kg/m\u00b2), class 2 (35\u00a0to 39.9 kg/m\u00b2), and class\u00a03, known as morbid obesity (\u226540 kg/m\u00b2)."}
{"id": "article-120320_5", "title": "Pharmacologic Therapy for Obesity -- Introduction", "content": "The primary approach\u00a0to addressing obesity\u00a0involves promoting weight loss\u00a0through behavioral therapy,\u00a0encompassing dietary changes, and adopting a healthy lifestyle with regular physical activity. Weight loss significantly reduces cardiovascular risk factors, aids disease prevention, and\u00a0enhances\u00a0self-esteem and overall functionality. While significant weight loss produces benefits in overall mortality, moderate\u00a0weight loss (5%-10%),\u00a0achievable\u00a0through lifestyle modifications and medications, has been\u00a0shown to significantly\u00a0improve\u00a0various conditions, including type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, nonalcoholic fatty liver disease, osteoarthritis, cancer, and sleep apnea. [2] [3] [4]", "contents": "Pharmacologic Therapy for Obesity -- Introduction. The primary approach\u00a0to addressing obesity\u00a0involves promoting weight loss\u00a0through behavioral therapy,\u00a0encompassing dietary changes, and adopting a healthy lifestyle with regular physical activity. Weight loss significantly reduces cardiovascular risk factors, aids disease prevention, and\u00a0enhances\u00a0self-esteem and overall functionality. While significant weight loss produces benefits in overall mortality, moderate\u00a0weight loss (5%-10%),\u00a0achievable\u00a0through lifestyle modifications and medications, has been\u00a0shown to significantly\u00a0improve\u00a0various conditions, including type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, nonalcoholic fatty liver disease, osteoarthritis, cancer, and sleep apnea. [2] [3] [4]"}
{"id": "article-120320_6", "title": "Pharmacologic Therapy for Obesity -- Introduction", "content": "In addition to these measures,\u00a0given\u00a0the challenges\u00a0associated with weight\u00a0loss and its maintenance, evidence-based pharmacologic therapy\u00a0is often deemed necessary to\u00a0achieve a\u00a0more effective and sustained response in managing obesity. Healthcare providers\u00a0are essential in engaging in a\u00a0shared decision-making process with patients, carefully considering\u00a0the risks and benefits. This collaborative approach ensures the selection of the most appropriate pharmacotherapy that aligns with the patient's profile.", "contents": "Pharmacologic Therapy for Obesity -- Introduction. In addition to these measures,\u00a0given\u00a0the challenges\u00a0associated with weight\u00a0loss and its maintenance, evidence-based pharmacologic therapy\u00a0is often deemed necessary to\u00a0achieve a\u00a0more effective and sustained response in managing obesity. Healthcare providers\u00a0are essential in engaging in a\u00a0shared decision-making process with patients, carefully considering\u00a0the risks and benefits. This collaborative approach ensures the selection of the most appropriate pharmacotherapy that aligns with the patient's profile."}
{"id": "article-120320_7", "title": "Pharmacologic Therapy for Obesity -- Introduction", "content": "When these methods prove ineffective, or if there is an urgent\u00a0need for weight loss and pharmacotherapy has not yielded the desired results, bariatric surgery can be considered. Bariatric surgery has demonstrated significant improvements in morbidity and mortality. Notably, patients who have previously failed to engage in a weight loss program or refuse assistance in a behavioral program are at a high\u00a0risk of\u00a0relapse following bariatric surgery. Therefore, surgical intervention may not be the recommended course of action in such cases.", "contents": "Pharmacologic Therapy for Obesity -- Introduction. When these methods prove ineffective, or if there is an urgent\u00a0need for weight loss and pharmacotherapy has not yielded the desired results, bariatric surgery can be considered. Bariatric surgery has demonstrated significant improvements in morbidity and mortality. Notably, patients who have previously failed to engage in a weight loss program or refuse assistance in a behavioral program are at a high\u00a0risk of\u00a0relapse following bariatric surgery. Therefore, surgical intervention may not be the recommended course of action in such cases."}
{"id": "article-120320_8", "title": "Pharmacologic Therapy for Obesity -- Issues of Concern", "content": "This\u00a0activity aims to assess the existing evidence regarding\u00a0currently available weight loss medications and examine substances that\u00a0lack proven benefits or could be harmful, leading to their discontinuation.", "contents": "Pharmacologic Therapy for Obesity -- Issues of Concern. This\u00a0activity aims to assess the existing evidence regarding\u00a0currently available weight loss medications and examine substances that\u00a0lack proven benefits or could be harmful, leading to their discontinuation."}
{"id": "article-120320_9", "title": "Pharmacologic Therapy for Obesity -- Issues of Concern", "content": "Obesity is a\u00a0widely discussed\u00a0topic,\u00a0with a\u00a0growing body of literature\u00a0exploring the effectiveness of multiple compounds in its treatment. However, limited evidence supports either the\u00a0endorsement or cessation\u00a0of various substances and dietary supplements. Consequently,\u00a0patients\u00a0persist in buying over-the-counter compounds, unaware that some can\u00a0be potentially\u00a0harmful.", "contents": "Pharmacologic Therapy for Obesity -- Issues of Concern. Obesity is a\u00a0widely discussed\u00a0topic,\u00a0with a\u00a0growing body of literature\u00a0exploring the effectiveness of multiple compounds in its treatment. However, limited evidence supports either the\u00a0endorsement or cessation\u00a0of various substances and dietary supplements. Consequently,\u00a0patients\u00a0persist in buying over-the-counter compounds, unaware that some can\u00a0be potentially\u00a0harmful."}
{"id": "article-120320_10", "title": "Pharmacologic Therapy for Obesity -- Issues of Concern", "content": "Clinicians\u00a0must caution\u00a0patients about the potential risks associated with weight-loss supplements and\u00a0carefully monitor\u00a0those\u00a0who use them. The\u00a0conclusions drawn from a 2015 review regarding some of these supplements\u00a0are outlined below: Green tea, Garcinia cambogia, conjugated linoleic acid, and chitosan\u00a0exhibited no\u00a0significant impact\u00a0on weight loss, indicating that healthcare professionals should not endorse their use. Data on the effectiveness of\u00a0chromium,\u00a0Gambisan, Hoodia gordonii , and Cynanchum auriculatum are inconclusive. Therefore,\u00a0clinicians should\u00a0refrain from recommending their use due to the lack of evidence and the potential risk of harm. [5]", "contents": "Pharmacologic Therapy for Obesity -- Issues of Concern. Clinicians\u00a0must caution\u00a0patients about the potential risks associated with weight-loss supplements and\u00a0carefully monitor\u00a0those\u00a0who use them. The\u00a0conclusions drawn from a 2015 review regarding some of these supplements\u00a0are outlined below: Green tea, Garcinia cambogia, conjugated linoleic acid, and chitosan\u00a0exhibited no\u00a0significant impact\u00a0on weight loss, indicating that healthcare professionals should not endorse their use. Data on the effectiveness of\u00a0chromium,\u00a0Gambisan, Hoodia gordonii , and Cynanchum auriculatum are inconclusive. Therefore,\u00a0clinicians should\u00a0refrain from recommending their use due to the lack of evidence and the potential risk of harm. [5]"}
{"id": "article-120320_11", "title": "Pharmacologic Therapy for Obesity -- Issues of Concern", "content": "Human chorionic gonadotropin (hCG) has been promoted as a potential weight loss therapy; however, clinical trials\u00a0do not support its efficacy. Several randomized trials have demonstrated that hCG injections or pills, when combined with a very low-calorie diet\u00a0(500 kcal/d), are\u00a0no more effective than a placebo in treating obesity. [6] The weight loss effect\u00a0is solely correlated to caloric restriction. Notably, very low-calorie diets are not\u00a0sustainable in the long term compared to conventional diets because\u00a0people tend to regain weight\u00a0rapidly upon discontinuing\u00a0such diets, and their\u00a0impact on other aspects of health remains unclear.", "contents": "Pharmacologic Therapy for Obesity -- Issues of Concern. Human chorionic gonadotropin (hCG) has been promoted as a potential weight loss therapy; however, clinical trials\u00a0do not support its efficacy. Several randomized trials have demonstrated that hCG injections or pills, when combined with a very low-calorie diet\u00a0(500 kcal/d), are\u00a0no more effective than a placebo in treating obesity. [6] The weight loss effect\u00a0is solely correlated to caloric restriction. Notably, very low-calorie diets are not\u00a0sustainable in the long term compared to conventional diets because\u00a0people tend to regain weight\u00a0rapidly upon discontinuing\u00a0such diets, and their\u00a0impact on other aspects of health remains unclear."}
{"id": "article-120320_12", "title": "Pharmacologic Therapy for Obesity -- Issues of Concern", "content": "Sibutramine was withdrawn from the US and European markets in 2010\u00a0following the Sibutramine Cardiovascular Outcomes (SCOUT)\u00a0trial, which revealed\u00a0a 16% increase in cardiovascular events in the medication group (11.4% versus 10% in the placebo). The Food and Drug Administration (FDA)\u00a0determined that the risks outweighed the benefits. Notably, the study population\u00a0included individuals aged\u00a055 years or older who were overweight or obese and\u00a0had a history of cardiovascular disease or type 2 diabetes mellitus, along with\u00a0one additional cardiovascular risk factor. [7] In some countries, sibutramine is still prescribed\u00a0to patients\u00a0who do not\u00a0meet any of the above criteria but under strict supervision and regulation.", "contents": "Pharmacologic Therapy for Obesity -- Issues of Concern. Sibutramine was withdrawn from the US and European markets in 2010\u00a0following the Sibutramine Cardiovascular Outcomes (SCOUT)\u00a0trial, which revealed\u00a0a 16% increase in cardiovascular events in the medication group (11.4% versus 10% in the placebo). The Food and Drug Administration (FDA)\u00a0determined that the risks outweighed the benefits. Notably, the study population\u00a0included individuals aged\u00a055 years or older who were overweight or obese and\u00a0had a history of cardiovascular disease or type 2 diabetes mellitus, along with\u00a0one additional cardiovascular risk factor. [7] In some countries, sibutramine is still prescribed\u00a0to patients\u00a0who do not\u00a0meet any of the above criteria but under strict supervision and regulation."}
{"id": "article-120320_13", "title": "Pharmacologic Therapy for Obesity -- Issues of Concern", "content": "Lorcaserin, another regulated weight-loss medication, was withdrawn in February 2020. This decision followed a safety clinical trial\u00a0involving 12,000 patients, which revealed a higher incidence of various types of cancer compared to the placebo group (7.7% versus 7.1% of patients), with the most common cancers being\u00a0pancreatic, colorectal, and lung cancer.\u00a0The FDA has not suggested any\u00a0specific cancer screening\u00a0for individuals\u00a0previously on lorcaserin apart from\u00a0age-appropriate screening protocols.", "contents": "Pharmacologic Therapy for Obesity -- Issues of Concern. Lorcaserin, another regulated weight-loss medication, was withdrawn in February 2020. This decision followed a safety clinical trial\u00a0involving 12,000 patients, which revealed a higher incidence of various types of cancer compared to the placebo group (7.7% versus 7.1% of patients), with the most common cancers being\u00a0pancreatic, colorectal, and lung cancer.\u00a0The FDA has not suggested any\u00a0specific cancer screening\u00a0for individuals\u00a0previously on lorcaserin apart from\u00a0age-appropriate screening protocols."}
{"id": "article-120320_14", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance", "content": "Sustained weight loss is rarely achievable solely through decreased food intake and increased energy expenditure due to counteractive adaptive biological responses. [8] [9] Decreases\u00a0in energy expenditure rates and increases in appetite\u00a0following weight loss are linked to\u00a0hormonal changes that\u00a0encourage weight regain.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance. Sustained weight loss is rarely achievable solely through decreased food intake and increased energy expenditure due to counteractive adaptive biological responses. [8] [9] Decreases\u00a0in energy expenditure rates and increases in appetite\u00a0following weight loss are linked to\u00a0hormonal changes that\u00a0encourage weight regain."}
{"id": "article-120320_15", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance", "content": "Despite\u00a0the challenges these adaptive mechanisms pose hindering\u00a0sustained weight loss, the recommendation\u00a0remains that all individuals adopt a healthy, well-balanced eating pattern. Ideally, this should be supervised,\u00a0coupled with maintaining a regular physical activity routine of at least 30 to 60 minutes of aerobic activity on most days of the week. This approach aids in\u00a0achieving weight and fat loss,\u00a0improving\u00a0cardiometabolic parameters, and supporting long-term weight maintenance. [10]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance. Despite\u00a0the challenges these adaptive mechanisms pose hindering\u00a0sustained weight loss, the recommendation\u00a0remains that all individuals adopt a healthy, well-balanced eating pattern. Ideally, this should be supervised,\u00a0coupled with maintaining a regular physical activity routine of at least 30 to 60 minutes of aerobic activity on most days of the week. This approach aids in\u00a0achieving weight and fat loss,\u00a0improving\u00a0cardiometabolic parameters, and supporting long-term weight maintenance. [10]"}
{"id": "article-120320_16", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy", "content": "Lifestyle intervention is paramount. Before starting weight loss drug therapy, it is important to establish a lifestyle intervention program,\u00a0preferably under\u00a0the close supervision\u00a0of a dietitian,\u00a0with long-term follow-up akin to that in\u00a0extended trials. [11] [12] While\u00a0discussing various lifestyle interventions is beyond the scope of this article, which focuses on medication therapy, it is important to note that pharmacologic therapy should be\u00a0considered\u00a0only after optimizing all nonpharmacologic approaches.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy. Lifestyle intervention is paramount. Before starting weight loss drug therapy, it is important to establish a lifestyle intervention program,\u00a0preferably under\u00a0the close supervision\u00a0of a dietitian,\u00a0with long-term follow-up akin to that in\u00a0extended trials. [11] [12] While\u00a0discussing various lifestyle interventions is beyond the scope of this article, which focuses on medication therapy, it is important to note that pharmacologic therapy should be\u00a0considered\u00a0only after optimizing all nonpharmacologic approaches."}
{"id": "article-120320_17", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy", "content": "Dietary adherence is essential for weight loss, regardless of the chosen diet. A study comparing\u00a0various types of diets found that the outcomes were directly proportional to the level of adherence exhibited by participants. [13]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy. Dietary adherence is essential for weight loss, regardless of the chosen diet. A study comparing\u00a0various types of diets found that the outcomes were directly proportional to the level of adherence exhibited by participants. [13]"}
{"id": "article-120320_18", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy", "content": "Very low-calorie diets can provide faster initial weight loss; however, the body's hormonal adaptation proves challenging to\u00a0sustain long-term. Following\u00a0a dietary\u00a0plan that\u00a0maintains\u00a0a negative calorie balance in the long term is essential.\u00a0Initiating medication therapy\u00a0can help overcome the stagnation\u00a0often observed after the initial months of diet and lifestyle intervention.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy. Very low-calorie diets can provide faster initial weight loss; however, the body's hormonal adaptation proves challenging to\u00a0sustain long-term. Following\u00a0a dietary\u00a0plan that\u00a0maintains\u00a0a negative calorie balance in the long term is essential.\u00a0Initiating medication therapy\u00a0can help overcome the stagnation\u00a0often observed after the initial months of diet and lifestyle intervention."}
{"id": "article-120320_19", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy", "content": "Intermittent fasting dietary patterns can be considered a\u00a0viable alternative, although studies have shown inconsistent efficacy. In a 1-year trial with 100 individuals with obesity, 3 groups were compared:\u00a0alternate-day fasting (patients alternated 25% of total energy consumed on fasting\u00a0days and 125% on free days) versus caloric restriction (ingesting 75% of total energy needs daily) versus nonintervention control. After 6 and 12 months, mean weight loss was comparable\u00a0for individuals in the alternate fasting group (-6.8% [95% CI, -9.1% to -4.5%] and -6.0% [95% CI, -8.5% to -3.6%, respectively]) and the daily constant calorie restriction group (-6.8% [95% CI, -9.1% to -4.6%] and\u00a0-5.3% [95% CI, -7.6% to -3.0%], respectively), when compared to the control group,\u00a0indicating similar efficacy. [14]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy. Intermittent fasting dietary patterns can be considered a\u00a0viable alternative, although studies have shown inconsistent efficacy. In a 1-year trial with 100 individuals with obesity, 3 groups were compared:\u00a0alternate-day fasting (patients alternated 25% of total energy consumed on fasting\u00a0days and 125% on free days) versus caloric restriction (ingesting 75% of total energy needs daily) versus nonintervention control. After 6 and 12 months, mean weight loss was comparable\u00a0for individuals in the alternate fasting group (-6.8% [95% CI, -9.1% to -4.5%] and -6.0% [95% CI, -8.5% to -3.6%, respectively]) and the daily constant calorie restriction group (-6.8% [95% CI, -9.1% to -4.6%] and\u00a0-5.3% [95% CI, -7.6% to -3.0%], respectively), when compared to the control group,\u00a0indicating similar efficacy. [14]"}
{"id": "article-120320_20", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy", "content": "Regardless of the diet or lifestyle program, continuous surveillance and follow-ups are essential. As\u00a0obesity\u00a0is a chronic disease with adaptative mechanisms, ongoing monitoring is mandatory to ensure better long-term outcomes.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy. Regardless of the diet or lifestyle program, continuous surveillance and follow-ups are essential. As\u00a0obesity\u00a0is a chronic disease with adaptative mechanisms, ongoing monitoring is mandatory to ensure better long-term outcomes."}
{"id": "article-120320_21", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy", "content": "Exercise is vital in maintaining a negative calorie balance by\u00a0increasing energy expenditure through physical activity and aiding in weight loss.\u00a0A 2017 study\u00a0highlighted that aerobic and anaerobic exercises combined\u00a0prove more efficient for weight loss than either type of exercise in isolation. [15] [16] The recommended guideline suggests engaging in approximately 30 minutes or more of exercise,\u00a05 to\u00a07 days a week, to prevent weight gain and\u00a0enhance\u00a0cardiovascular health\u00a0in adults. [17]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy. Exercise is vital in maintaining a negative calorie balance by\u00a0increasing energy expenditure through physical activity and aiding in weight loss.\u00a0A 2017 study\u00a0highlighted that aerobic and anaerobic exercises combined\u00a0prove more efficient for weight loss than either type of exercise in isolation. [15] [16] The recommended guideline suggests engaging in approximately 30 minutes or more of exercise,\u00a05 to\u00a07 days a week, to prevent weight gain and\u00a0enhance\u00a0cardiovascular health\u00a0in adults. [17]"}
{"id": "article-120320_22", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy", "content": "Behavior\u00a0therapy is crucial in\u00a0assisting patients with long-term changes in their eating\u00a0habits. This approach\u00a0involves\u00a0modifying and monitoring food intake, adapting\u00a0physical activity, and controlling environmental stimuli that trigger binge eating. Individuals\u00a0are aided in\u00a0developing healthier eating behaviors and sustaining long-lasting lifestyle changes.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Nonpharmacologic Therapy. Behavior\u00a0therapy is crucial in\u00a0assisting patients with long-term changes in their eating\u00a0habits. This approach\u00a0involves\u00a0modifying and monitoring food intake, adapting\u00a0physical activity, and controlling environmental stimuli that trigger binge eating. Individuals\u00a0are aided in\u00a0developing healthier eating behaviors and sustaining long-lasting lifestyle changes."}
{"id": "article-120320_23", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy", "content": "Initiating approved weight loss medications can be beneficial to sustain the positive effects of weight loss following lifestyle changes. This is particularly important if a struggle to maintain weight loss or if weight regain occurs. Pharmacologic therapy can also be considered\u00a0alongside\u00a0initiating a weight loss program, following a thorough discussion of the risks and benefits with the patients.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy. Initiating approved weight loss medications can be beneficial to sustain the positive effects of weight loss following lifestyle changes. This is particularly important if a struggle to maintain weight loss or if weight regain occurs. Pharmacologic therapy can also be considered\u00a0alongside\u00a0initiating a weight loss program, following a thorough discussion of the risks and benefits with the patients."}
{"id": "article-120320_24", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy", "content": "Drug therapy can\u00a0be\u00a0considered for individuals with a BMI greater than 30 kg/m or a BMI of 27 to 29.9 kg/m in the presence of weight-related complications. This is especially applicable for patients who have been unable to achieve their weight loss goals (at least 5% of total body weight in 3 to 6 months)\u00a0despite\u00a0undergoing comprehensive lifestyle intervention. Notably,\u00a0initiating drug therapy should always be\u00a0coupled with\u00a0the\u00a0continuation\u00a0of behavioral and lifestyle changes. Without this combination, medications\u00a0typically yield\u00a0low success rates. [18] [19]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy. Drug therapy can\u00a0be\u00a0considered for individuals with a BMI greater than 30 kg/m or a BMI of 27 to 29.9 kg/m in the presence of weight-related complications. This is especially applicable for patients who have been unable to achieve their weight loss goals (at least 5% of total body weight in 3 to 6 months)\u00a0despite\u00a0undergoing comprehensive lifestyle intervention. Notably,\u00a0initiating drug therapy should always be\u00a0coupled with\u00a0the\u00a0continuation\u00a0of behavioral and lifestyle changes. Without this combination, medications\u00a0typically yield\u00a0low success rates. [18] [19]"}
{"id": "article-120320_25", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy", "content": "Approved medications facilitate\u00a0weight loss\u00a0by decreasing appetite and hunger, increasing satiety, and reducing caloric absorption or intake. Nevertheless, achieving long-term weight maintenance and overcoming the physiologic trend of regaining weight remains a significant challenge.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy. Approved medications facilitate\u00a0weight loss\u00a0by decreasing appetite and hunger, increasing satiety, and reducing caloric absorption or intake. Nevertheless, achieving long-term weight maintenance and overcoming the physiologic trend of regaining weight remains a significant challenge."}
{"id": "article-120320_26", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy", "content": "When considering the initiation of pharmacologic therapy, an individualized approach is necessary,\u00a0factoring\u00a0in the patient's\u00a0comorbidities, preferences, insurance coverage, and costs. Generally, single agents are preferred over combination therapy. However, different medications can\u00a0be\u00a0combined to\u00a0enhance the response, provided the clinician carefully evaluates safety and interaction profiles. [20]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy. When considering the initiation of pharmacologic therapy, an individualized approach is necessary,\u00a0factoring\u00a0in the patient's\u00a0comorbidities, preferences, insurance coverage, and costs. Generally, single agents are preferred over combination therapy. However, different medications can\u00a0be\u00a0combined to\u00a0enhance the response, provided the clinician carefully evaluates safety and interaction profiles. [20]"}
{"id": "article-120320_27", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy", "content": "In clinical studies of weight loss medications, a 5% to 10% reduction in body weight has traditionally been considered significant. This percentage aligns with the FDA's recommendations in trials and is linked to notable clinical improvements in metabolic risk profiles. [21] Additionally, secondary weight loss outcomes in these trials have\u00a0examined the proportion of individuals\u00a0achieving a 10% or\u00a0greater weight loss and changes in weight from baseline. [21]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy. In clinical studies of weight loss medications, a 5% to 10% reduction in body weight has traditionally been considered significant. This percentage aligns with the FDA's recommendations in trials and is linked to notable clinical improvements in metabolic risk profiles. [21] Additionally, secondary weight loss outcomes in these trials have\u00a0examined the proportion of individuals\u00a0achieving a 10% or\u00a0greater weight loss and changes in weight from baseline. [21]"}
{"id": "article-120320_28", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy", "content": "Obesity medication therapy goals\u00a0must be realistic to prevent frustration and treatment discontinuation.\u00a0The focus should be on\u00a0short-term and\u00a0long-term weight reduction, preventing weight gain, improving health parameters, and\u00a0managing\u00a0side effects. [22] When starting weight loss therapy, it is\u00a0crucial to emphasize that drug responses and side effects can vary significantly among patients. Moreover, patients should be informed that reaching a plateau after initial weight loss is common, and if drug treatment is interrupted, weight regain can be expected.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Pharmacologic Therapy. Obesity medication therapy goals\u00a0must be realistic to prevent frustration and treatment discontinuation.\u00a0The focus should be on\u00a0short-term and\u00a0long-term weight reduction, preventing weight gain, improving health parameters, and\u00a0managing\u00a0side effects. [22] When starting weight loss therapy, it is\u00a0crucial to emphasize that drug responses and side effects can vary significantly among patients. Moreover, patients should be informed that reaching a plateau after initial weight loss is common, and if drug treatment is interrupted, weight regain can be expected."}
{"id": "article-120320_29", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide", "content": "Marketed\u00a0under Ozempic, Rybelsus, and Wegovy, semaglutide is the\u00a0latest\u00a0long-acting glucagon-like peptide-1 receptor agonist\u00a0(GLP-1RA) approved by the Food and Drug Administration (FDA) for obesity treatment. It has\u00a0shown significant weight loss benefits in patients with and without diabetes, along with improvements in glycemic control.\u00a0While oral and injectable forms are FDA-approved for diabetes treatment and have\u00a0demonstrated weight loss effects, only the subcutaneous preparation has received FDA approval specifically for obesity treatment. [15] Several studies have\u00a0demonstrated the\u00a0effectiveness\u00a0of semaglutide in promoting weight loss among\u00a0individuals who are overweight or obese,\u00a0irrespective of whether they have type 2 diabetes.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide. Marketed\u00a0under Ozempic, Rybelsus, and Wegovy, semaglutide is the\u00a0latest\u00a0long-acting glucagon-like peptide-1 receptor agonist\u00a0(GLP-1RA) approved by the Food and Drug Administration (FDA) for obesity treatment. It has\u00a0shown significant weight loss benefits in patients with and without diabetes, along with improvements in glycemic control.\u00a0While oral and injectable forms are FDA-approved for diabetes treatment and have\u00a0demonstrated weight loss effects, only the subcutaneous preparation has received FDA approval specifically for obesity treatment. [15] Several studies have\u00a0demonstrated the\u00a0effectiveness\u00a0of semaglutide in promoting weight loss among\u00a0individuals who are overweight or obese,\u00a0irrespective of whether they have type 2 diabetes."}
{"id": "article-120320_30", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide", "content": "In the STEP 1 trial, 1961 adults without diabetes and with obesity (BMI \u226530 kg/m2 or \u226527\u00a0kg/m2 with at least\u00a01 weight-related comorbidity) participated in a randomized controlled trial. Patients were assigned to 68 weeks of therapy with weekly\u00a0subcutaneous\u00a02.4 mg semaglutide or placebo.\u00a0Individuals in the semaglutide group\u00a0experienced a significant weight loss of\u00a015.3 kg\u00a0compared to\u00a02.6 kg in the placebo group. The estimated treatment difference was 12.7 kg, 95% CI -13.7 to -11.7 kg. More patients in the semaglutide group had weight loss greater than or equal to 5 (86.4% versus 31.5%), greater than or equal to 10 (69.1% versus 12.0%), and greater than or equal to 15 (50.5% versus 4.9%) compared to the placebo group. [15]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide. In the STEP 1 trial, 1961 adults without diabetes and with obesity (BMI \u226530 kg/m2 or \u226527\u00a0kg/m2 with at least\u00a01 weight-related comorbidity) participated in a randomized controlled trial. Patients were assigned to 68 weeks of therapy with weekly\u00a0subcutaneous\u00a02.4 mg semaglutide or placebo.\u00a0Individuals in the semaglutide group\u00a0experienced a significant weight loss of\u00a015.3 kg\u00a0compared to\u00a02.6 kg in the placebo group. The estimated treatment difference was 12.7 kg, 95% CI -13.7 to -11.7 kg. More patients in the semaglutide group had weight loss greater than or equal to 5 (86.4% versus 31.5%), greater than or equal to 10 (69.1% versus 12.0%), and greater than or equal to 15 (50.5% versus 4.9%) compared to the placebo group. [15]"}
{"id": "article-120320_31", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide", "content": "In the STEP 2 trial, over 1200 patients with type 2 diabetes and obesity were randomized to receive weekly semaglutide doses of 1 mg and 2.4 mg and compared to a placebo. The estimated treatment difference for semaglutide 2.4 mg (-9.6%) versus placebo (-3.4%) was \u22126.2 percentage points\u00a0(95% CI \u22127\u00b73 to \u22125\u00b72; p<0\u00b70001). [23]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide. In the STEP 2 trial, over 1200 patients with type 2 diabetes and obesity were randomized to receive weekly semaglutide doses of 1 mg and 2.4 mg and compared to a placebo. The estimated treatment difference for semaglutide 2.4 mg (-9.6%) versus placebo (-3.4%) was \u22126.2 percentage points\u00a0(95% CI \u22127\u00b73 to \u22125\u00b72; p<0\u00b70001). [23]"}
{"id": "article-120320_32", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide", "content": "Semaglutide\u00a0shares\u00a0a similar side effect profile\u00a0with other GLP-1 agonist agents, including symptoms such as nausea and vomiting. Patients are advised to report any persistent or severe side effects to their healthcare\u00a0professional promptly to ensure proper guidance and adjustment of the treatment plan if necessary. Dosing The injectable formulation of semaglutide includes subcutaneous weekly injections, starting with an initial dose of 0.25 mg for 4 weeks, followed by incremental increases every 4 weeks (0.5, 1.17, 2.4 mg) until reaching the maximum tolerated dose. In patients with type 2 diabetes, glycemic levels should also be monitored before titration, and dosing of other concomitant hypoglycemic agents should be adjusted to prevent hypoglycemia.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide. Semaglutide\u00a0shares\u00a0a similar side effect profile\u00a0with other GLP-1 agonist agents, including symptoms such as nausea and vomiting. Patients are advised to report any persistent or severe side effects to their healthcare\u00a0professional promptly to ensure proper guidance and adjustment of the treatment plan if necessary. Dosing The injectable formulation of semaglutide includes subcutaneous weekly injections, starting with an initial dose of 0.25 mg for 4 weeks, followed by incremental increases every 4 weeks (0.5, 1.17, 2.4 mg) until reaching the maximum tolerated dose. In patients with type 2 diabetes, glycemic levels should also be monitored before titration, and dosing of other concomitant hypoglycemic agents should be adjusted to prevent hypoglycemia."}
{"id": "article-120320_33", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide", "content": "Contraindication Individuals\u00a0with a personal history of pancreatitis or a personal or familial history of medullary thyroid cancer or multiple endocrine neoplasia (MEN) 2A or 2B should\u00a0avoid semaglutide. Patients should be\u00a0educated about the symptoms of pancreatitis or gallbladder pathologies.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide. Contraindication Individuals\u00a0with a personal history of pancreatitis or a personal or familial history of medullary thyroid cancer or multiple endocrine neoplasia (MEN) 2A or 2B should\u00a0avoid semaglutide. Patients should be\u00a0educated about the symptoms of pancreatitis or gallbladder pathologies."}
{"id": "article-120320_34", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide", "content": "Similar to\u00a0other GLP-1 agonists, semaglutide has also been shown to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. [24]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Semaglutide. Similar to\u00a0other GLP-1 agonists, semaglutide has also been shown to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. [24]"}
{"id": "article-120320_35", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "Liraglutide\u00a0was the first GLP-1RA to\u00a0receive approval for\u00a0treating\u00a0obesity in patients without diabetes. Subsequently, in 2021, Semaglutide became the second GLP-1RA to be approved for obesity treatment, extending its use to all patients without requiring a diabetes diagnosis.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. Liraglutide\u00a0was the first GLP-1RA to\u00a0receive approval for\u00a0treating\u00a0obesity in patients without diabetes. Subsequently, in 2021, Semaglutide became the second GLP-1RA to be approved for obesity treatment, extending its use to all patients without requiring a diabetes diagnosis."}
{"id": "article-120320_36", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "Glucagon-like peptide (GLP-1), an incretin peptide secreted by the gut\u00a0after\u00a0oral food intake, plays a significant role. It inhibits gastric emptying and glucagon release\u00a0while inducing glucose-dependent insulin release from the pancreas's beta cells. The GLP-1RAs\u00a0are considered a second or third\u00a0option\u00a0in\u00a0treating type 2 diabetes when glycemic control is not achieved. Particularly beneficial for patients with diabetes who are overweight or obese, GLP-1RAs, along with sodium-glucose cotransporter 2 (SGLT2) inhibitors,\u00a0are ideal\u00a0due to their proven weight loss effects.\u00a0Notably, in patients without diabetes, the use of SGLT2 inhibitors for weight loss is still off-label.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. Glucagon-like peptide (GLP-1), an incretin peptide secreted by the gut\u00a0after\u00a0oral food intake, plays a significant role. It inhibits gastric emptying and glucagon release\u00a0while inducing glucose-dependent insulin release from the pancreas's beta cells. The GLP-1RAs\u00a0are considered a second or third\u00a0option\u00a0in\u00a0treating type 2 diabetes when glycemic control is not achieved. Particularly beneficial for patients with diabetes who are overweight or obese, GLP-1RAs, along with sodium-glucose cotransporter 2 (SGLT2) inhibitors,\u00a0are ideal\u00a0due to their proven weight loss effects.\u00a0Notably, in patients without diabetes, the use of SGLT2 inhibitors for weight loss is still off-label."}
{"id": "article-120320_37", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "For obesity treatment, the GLP-1RAs are approved at higher doses than\u00a0those recommended for diabetes treatment. They are approved for obesity treatment in adults with a BMI greater than or equal to 30 kg/m\u00a0or with a BMI greater than or equal to 27 kg/m when at least\u00a01 weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidemia, osteoarthritis) is present. Liraglutide, approved for obesity,\u00a0has a daily dose of 3 mg,\u00a0although\u00a0an initial dose of 1.2 mg can\u00a0yield\u00a0weight loss and can be escalated based on tolerability. Semaglutide, approved for obesity,\u00a0comes in a convenient 2.4 mg once-weekly dosage. Often, patients achieve weight loss below the maximum dose, experiencing fewer side effects and maintaining adequate glucose control.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. For obesity treatment, the GLP-1RAs are approved at higher doses than\u00a0those recommended for diabetes treatment. They are approved for obesity treatment in adults with a BMI greater than or equal to 30 kg/m\u00a0or with a BMI greater than or equal to 27 kg/m when at least\u00a01 weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidemia, osteoarthritis) is present. Liraglutide, approved for obesity,\u00a0has a daily dose of 3 mg,\u00a0although\u00a0an initial dose of 1.2 mg can\u00a0yield\u00a0weight loss and can be escalated based on tolerability. Semaglutide, approved for obesity,\u00a0comes in a convenient 2.4 mg once-weekly dosage. Often, patients achieve weight loss below the maximum dose, experiencing fewer side effects and maintaining adequate glucose control."}
{"id": "article-120320_38", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "Randomized controlled trials have\u00a0demonstrated liraglutide's efficacy in diabetes management and weight loss.\u00a0Multiple studies have\u00a0shown sustained weight loss and additional cardiovascular benefits over a maximum duration of 2 years.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. Randomized controlled trials have\u00a0demonstrated liraglutide's efficacy in diabetes management and weight loss.\u00a0Multiple studies have\u00a0shown sustained weight loss and additional cardiovascular benefits over a maximum duration of 2 years."}
{"id": "article-120320_39", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "In a 20-week study\u00a0involving\u00a0564 patients, liraglutide\u00a0at\u00a04 different daily doses (1.2, 1.8, 2.4, and 3 mg) showed\u00a0dose-dependent weight loss compared to placebo or open-label orlistat, with weight losses of 5.8 kg and 3.8 kg more than placebo and orlistat, respectively.\u00a0These results were consistent in a\u00a02-year extension study, where patients on higher doses (2.4 mg and 3.0 mg)\u00a0maintained a weight loss of 7.8 kg at the end of the study (total n=92 patients\u00a0on the higher doses). Notably, liraglutide 3.0 mg also substantially reduced body fat by 15.4% while preserving lean tissue, which decreased by only 2.0%.\u00a0Moreover, the prevalence of prediabetes and metabolic syndrome\u00a0was reduced by 52% and 59%, respectively, after 2 years, accompanied by improved blood pressure and lipid levels. [25]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. In a 20-week study\u00a0involving\u00a0564 patients, liraglutide\u00a0at\u00a04 different daily doses (1.2, 1.8, 2.4, and 3 mg) showed\u00a0dose-dependent weight loss compared to placebo or open-label orlistat, with weight losses of 5.8 kg and 3.8 kg more than placebo and orlistat, respectively.\u00a0These results were consistent in a\u00a02-year extension study, where patients on higher doses (2.4 mg and 3.0 mg)\u00a0maintained a weight loss of 7.8 kg at the end of the study (total n=92 patients\u00a0on the higher doses). Notably, liraglutide 3.0 mg also substantially reduced body fat by 15.4% while preserving lean tissue, which decreased by only 2.0%.\u00a0Moreover, the prevalence of prediabetes and metabolic syndrome\u00a0was reduced by 52% and 59%, respectively, after 2 years, accompanied by improved blood pressure and lipid levels. [25]"}
{"id": "article-120320_40", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "In a 56-week trial\u00a0involving 3731 patients with a BMI greater than or equal to 30 kg/m\u00a0or greater than or equal to 27 kg/m\u00a0with dyslipidemia or hypertension, liraglutide 3 mg was compared with a placebo. The results demonstrated a mean weight loss\u00a0of\u00a08.0 kg versus 2.6 kg\u00a0in the placebo group. Additionally, liraglutide improved several cardiometabolic risk factors, glycated hemoglobin (HgbA1C) levels, and quality of life. [26]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. In a 56-week trial\u00a0involving 3731 patients with a BMI greater than or equal to 30 kg/m\u00a0or greater than or equal to 27 kg/m\u00a0with dyslipidemia or hypertension, liraglutide 3 mg was compared with a placebo. The results demonstrated a mean weight loss\u00a0of\u00a08.0 kg versus 2.6 kg\u00a0in the placebo group. Additionally, liraglutide improved several cardiometabolic risk factors, glycated hemoglobin (HgbA1C) levels, and quality of life. [26]"}
{"id": "article-120320_41", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "The LEADER trial showed that liraglutide, even at a lower dose than the recommended dosage for obesity\u00a0(1.8 mg versus 3 mg), reduced major cardiovascular events, including cardiovascular-related deaths, nonfatal myocardial infarction, or nonfatal stroke, in patients with type 2 diabetes. [27] However, there is currently no available cardiovascular outcome data for patients with obesity\u00a0who do not have diabetes.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. The LEADER trial showed that liraglutide, even at a lower dose than the recommended dosage for obesity\u00a0(1.8 mg versus 3 mg), reduced major cardiovascular events, including cardiovascular-related deaths, nonfatal myocardial infarction, or nonfatal stroke, in patients with type 2 diabetes. [27] However, there is currently no available cardiovascular outcome data for patients with obesity\u00a0who do not have diabetes."}
{"id": "article-120320_42", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "The primary side effects of liraglutide are mainly gastrointestinal, including\u00a0nausea and vomiting,\u00a0often more pronounced at the beginning of therapy or after dose increments. The symptoms appear to be dose-dependent. Sometimes, selecting an\u00a0intermediate dose that patients can tolerate while\u00a0preserving the medication's positive effects may be a practical approach.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. The primary side effects of liraglutide are mainly gastrointestinal, including\u00a0nausea and vomiting,\u00a0often more pronounced at the beginning of therapy or after dose increments. The symptoms appear to be dose-dependent. Sometimes, selecting an\u00a0intermediate dose that patients can tolerate while\u00a0preserving the medication's positive effects may be a practical approach."}
{"id": "article-120320_43", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "While\u00a0there is an observed finding of pancreatitis, a definitive causal relationship has not been established. Furthermore, gallbladder\u00a0disease can predispose to cholelithiasis, and persistent nausea and vomiting can lead to dehydration\u00a0if the medication is not discontinued. [27] Liraglutide has\u00a0demonstrated\u00a0an association with\u00a0malignant medullary carcinoma in rodent trials; however, this\u00a0correlation remains unproven in humans. Dosing Liraglutide is administered subcutaneously, starting with an initial dose of 0.6 mg daily for\u00a01 week,\u00a0followed by weekly increment increases of 0.6 mg until reaching the recommended dose of 3 mg. While many patients cannot tolerate the highest dose, they can still experience benefits\u00a0at lower dosages within their maximum tolerance level.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. While\u00a0there is an observed finding of pancreatitis, a definitive causal relationship has not been established. Furthermore, gallbladder\u00a0disease can predispose to cholelithiasis, and persistent nausea and vomiting can lead to dehydration\u00a0if the medication is not discontinued. [27] Liraglutide has\u00a0demonstrated\u00a0an association with\u00a0malignant medullary carcinoma in rodent trials; however, this\u00a0correlation remains unproven in humans. Dosing Liraglutide is administered subcutaneously, starting with an initial dose of 0.6 mg daily for\u00a01 week,\u00a0followed by weekly increment increases of 0.6 mg until reaching the recommended dose of 3 mg. While many patients cannot tolerate the highest dose, they can still experience benefits\u00a0at lower dosages within their maximum tolerance level."}
{"id": "article-120320_44", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "Contraindications Several\u00a0other GLP-1 receptor agonists with similar responses in glucose control, weight loss, and cardiovascular benefits have entered the market. However,\u00a0these medications\u00a0have not\u00a0obtained approval for treating overweight or obese patients without diabetes. Researchers have not studied the medication's effects during pregnancy,\u00a0making it contraindicated in pregnant individuals. It is also not recommended for patients with a personal or family history of medullary thyroid cancer or\u00a0MEN 2A or 2B.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. Contraindications Several\u00a0other GLP-1 receptor agonists with similar responses in glucose control, weight loss, and cardiovascular benefits have entered the market. However,\u00a0these medications\u00a0have not\u00a0obtained approval for treating overweight or obese patients without diabetes. Researchers have not studied the medication's effects during pregnancy,\u00a0making it contraindicated in pregnant individuals. It is also not recommended for patients with a personal or family history of medullary thyroid cancer or\u00a0MEN 2A or 2B."}
{"id": "article-120320_45", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide", "content": "Semaglutide and liraglutide were compared in a randomized controlled trial (STEP 8) which included 338 adults with a BMI greater than or equal to 30 kg/m\u00b2 (or \u226527 kg/m\u00b2 with \u22651 weight-related comorbidity) assigned to once-weekly subcutaneous semaglutide 2.4 mg or placebo), or once-daily subcutaneous 3.0 mg liraglutide, or placebo. At the end of 68 weeks, participants in the semaglutide group\u00a0demonstrated\u00a0greater weight loss than the liraglutide group (-15.8% versus -6.4%; treatment difference -9.4% [95% CI -12.0 to -6.8]). In contrast, the weight change in the placebo group was -1.9 percent.\u00a0Additionally, the semaglutide group\u00a0exhibited a higher percentage of individuals achieving 10%, 15%, or 20% or more weight loss [28] .", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Liraglutide. Semaglutide and liraglutide were compared in a randomized controlled trial (STEP 8) which included 338 adults with a BMI greater than or equal to 30 kg/m\u00b2 (or \u226527 kg/m\u00b2 with \u22651 weight-related comorbidity) assigned to once-weekly subcutaneous semaglutide 2.4 mg or placebo), or once-daily subcutaneous 3.0 mg liraglutide, or placebo. At the end of 68 weeks, participants in the semaglutide group\u00a0demonstrated\u00a0greater weight loss than the liraglutide group (-15.8% versus -6.4%; treatment difference -9.4% [95% CI -12.0 to -6.8]). In contrast, the weight change in the placebo group was -1.9 percent.\u00a0Additionally, the semaglutide group\u00a0exhibited a higher percentage of individuals achieving 10%, 15%, or 20% or more weight loss [28] ."}
{"id": "article-120320_46", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat", "content": "Orlistat functions by inhibiting pancreatic lipases, disrupting fat digestion in the gut. Consequently, fat molecules are not fully hydrolyzed and remain unabsorbed. The extent of weight loss correlates with the calories lost\u00a0through fecal fat excretion, representing up to a 30% reduction in calorie intake on an average diet.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat. Orlistat functions by inhibiting pancreatic lipases, disrupting fat digestion in the gut. Consequently, fat molecules are not fully hydrolyzed and remain unabsorbed. The extent of weight loss correlates with the calories lost\u00a0through fecal fat excretion, representing up to a 30% reduction in calorie intake on an average diet."}
{"id": "article-120320_47", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat", "content": "Several studies, including randomized control trials and meta-analyses, have demonstrated the efficacy of orlistat. [29] [30] In a meta-analysis of 12 trials, the orlistat group\u00a0exhibited a mean\u00a0weight loss of 8%, in contrast to 5%\u00a0in the placebo group, even with\u00a0comparable behavioral\u00a0interventions. [31] Furthermore, subjects were able to\u00a0sustain their weight loss with continuous therapy for up to 24 to 36 months.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat. Several studies, including randomized control trials and meta-analyses, have demonstrated the efficacy of orlistat. [29] [30] In a meta-analysis of 12 trials, the orlistat group\u00a0exhibited a mean\u00a0weight loss of 8%, in contrast to 5%\u00a0in the placebo group, even with\u00a0comparable behavioral\u00a0interventions. [31] Furthermore, subjects were able to\u00a0sustain their weight loss with continuous therapy for up to 24 to 36 months."}
{"id": "article-120320_48", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat", "content": "In the Xendos study, 3304 patients who were overweight were randomly assigned to orlistat or placebo. Notably, 21% of these patients had impaired glucose tolerance.\u00a0Over the first year, researchers observed a substantial disparity between groups, with the orlistat group experiencing an 11% reduction from baseline, compared to 6% in the placebo group. Although this\u00a0gap narrowed\u00a0during the\u00a0subsequent\u00a03 years of the trial, the orlistat group\u00a0maintained a 6.9% reduction\u00a0from\u00a0baseline, while the placebo showed\u00a0a 4.1% reduction. Despite the diminished difference by the study's end, patients in the orlistat group had a lower incidence of diabetes than the placebo group (6.2% versus\u00a09%). In trials involving patients with diabetes, orlistat also\u00a0led to greater weight loss and lower HgbA1c levels at 1\u00a0year compared to the placebo groups. [32]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat. In the Xendos study, 3304 patients who were overweight were randomly assigned to orlistat or placebo. Notably, 21% of these patients had impaired glucose tolerance.\u00a0Over the first year, researchers observed a substantial disparity between groups, with the orlistat group experiencing an 11% reduction from baseline, compared to 6% in the placebo group. Although this\u00a0gap narrowed\u00a0during the\u00a0subsequent\u00a03 years of the trial, the orlistat group\u00a0maintained a 6.9% reduction\u00a0from\u00a0baseline, while the placebo showed\u00a0a 4.1% reduction. Despite the diminished difference by the study's end, patients in the orlistat group had a lower incidence of diabetes than the placebo group (6.2% versus\u00a09%). In trials involving patients with diabetes, orlistat also\u00a0led to greater weight loss and lower HgbA1c levels at 1\u00a0year compared to the placebo groups. [32]"}
{"id": "article-120320_49", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat", "content": "Additional\u00a0benefits of orlistat have been\u00a0observed in\u00a0various studies. A systematic review highlighted a decrease in systolic and diastolic blood pressure in individuals taking prlistat compared to placebo (with a weighted difference of -2.5 and -1.9 mm Hg, respectively). [33] Moreover, in a multicenter trial, orlistat\u00a0demonstrated\u00a0improvements in serum lipid values,\u00a0including a 5% to 10% reduction in\u00a0low-density lipoprotein (LDL) cholesterol in patients treated with orlistat and a low-fat diet\u00a0over 48 weeks from baseline. [34] Dosing: The recommended dose is 120 mg, taken 3 times daily,\u00a0accompanying\u00a0each meal. Patients are strongly advised to take a daily multivitamin at bedtime to compensate for the reduced absorption of fat-soluble vitamins associated with chronic orlistat use. This medication is available over the counter in many countries,\u00a0including the United States.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat. Additional\u00a0benefits of orlistat have been\u00a0observed in\u00a0various studies. A systematic review highlighted a decrease in systolic and diastolic blood pressure in individuals taking prlistat compared to placebo (with a weighted difference of -2.5 and -1.9 mm Hg, respectively). [33] Moreover, in a multicenter trial, orlistat\u00a0demonstrated\u00a0improvements in serum lipid values,\u00a0including a 5% to 10% reduction in\u00a0low-density lipoprotein (LDL) cholesterol in patients treated with orlistat and a low-fat diet\u00a0over 48 weeks from baseline. [34] Dosing: The recommended dose is 120 mg, taken 3 times daily,\u00a0accompanying\u00a0each meal. Patients are strongly advised to take a daily multivitamin at bedtime to compensate for the reduced absorption of fat-soluble vitamins associated with chronic orlistat use. This medication is available over the counter in many countries,\u00a0including the United States."}
{"id": "article-120320_50", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat", "content": "Contraindications : Patients can\u00a0utilize orlistat for up to 4 years in\u00a0obesity treatment. If therapy\u00a0extends beyond this period, it is essential to discuss it with the patient, informing them about the absence of\u00a0extended studies. The medication has not\u00a0undergone\u00a0studies in pregnant individuals and\u00a0should not be considered\u00a0for patients with chronic malabsorption, cholestasis, or calcium oxalate stones.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat. Contraindications : Patients can\u00a0utilize orlistat for up to 4 years in\u00a0obesity treatment. If therapy\u00a0extends beyond this period, it is essential to discuss it with the patient, informing them about the absence of\u00a0extended studies. The medication has not\u00a0undergone\u00a0studies in pregnant individuals and\u00a0should not be considered\u00a0for patients with chronic malabsorption, cholestasis, or calcium oxalate stones."}
{"id": "article-120320_51", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat", "content": "Commonly observed side effects of orlistat are  gastrointestinal, including abdominal cramps, increased flatulence, and fecal incontinence. These effects are more prevalent\u00a0early in its use and\u00a0often diminish\u00a0when patients adhere to a low-fat diet (<30%) without\u00a0compromising weight loss benefits. [35] Although the FDA\u00a0recorded 13 instances\u00a0of severe liver injury,\u00a0establishing a\u00a0direct cause\u00a0has proven challenging due to patients\u00a0concurrently taking other medications and having underlying medical conditions that could contribute to such incidents. However, individuals using orlistat should understand\u00a0the need to contact their healthcare\u00a0professional if signs or symptoms of liver injury occur. There\u00a0is no\u00a0heightened\u00a0risk of cholelithiasis, cardiovascular issues, or psychiatric events associated with orlistat usage.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat. Commonly observed side effects of orlistat are  gastrointestinal, including abdominal cramps, increased flatulence, and fecal incontinence. These effects are more prevalent\u00a0early in its use and\u00a0often diminish\u00a0when patients adhere to a low-fat diet (<30%) without\u00a0compromising weight loss benefits. [35] Although the FDA\u00a0recorded 13 instances\u00a0of severe liver injury,\u00a0establishing a\u00a0direct cause\u00a0has proven challenging due to patients\u00a0concurrently taking other medications and having underlying medical conditions that could contribute to such incidents. However, individuals using orlistat should understand\u00a0the need to contact their healthcare\u00a0professional if signs or symptoms of liver injury occur. There\u00a0is no\u00a0heightened\u00a0risk of cholelithiasis, cardiovascular issues, or psychiatric events associated with orlistat usage."}
{"id": "article-120320_52", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat", "content": "Orlistat's mechanism of fat fecal excretion can impair the levels of fat-soluble vitamins (A, D, E, K) and\u00a0beta-carotene. Additionally, it can prolong the international normalized ratio (INR) and prothrombin time in patients taking warfarin by reducing vitamin K levels, requiring a reduction of warfarin\u00a0dosage and\u00a0careful monitoring. [36]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat. Orlistat's mechanism of fat fecal excretion can impair the levels of fat-soluble vitamins (A, D, E, K) and\u00a0beta-carotene. Additionally, it can prolong the international normalized ratio (INR) and prothrombin time in patients taking warfarin by reducing vitamin K levels, requiring a reduction of warfarin\u00a0dosage and\u00a0careful monitoring. [36]"}
{"id": "article-120320_53", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat", "content": "Fat malabsorption leads to the binding of enteric calcium with fat excreted in stools. Consequently, intestinal oxalate becomes more\u00a0accessible for\u00a0absorption and subsequent excretion in the urine. Excessive free oxalate can\u00a0accumulate in the renal parenchyma, potentially resulting in acute nephrocalcinosis and acute kidney injury. [37]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Orlistat. Fat malabsorption leads to the binding of enteric calcium with fat excreted in stools. Consequently, intestinal oxalate becomes more\u00a0accessible for\u00a0absorption and subsequent excretion in the urine. Excessive free oxalate can\u00a0accumulate in the renal parenchyma, potentially resulting in acute nephrocalcinosis and acute kidney injury. [37]"}
{"id": "article-120320_54", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Combination therapies", "content": "Given the chronic\u00a0nature of\u00a0obesity\u00a0requiring\u00a0prolonged treatment and the potential side effects associated with various medications, combination\u00a0therapies have been suggested as a more practical approach. This involves using lower doses of\u00a02 medications, allowing 1 drug to offset the potential\u00a0side effects of the other\u00a0while maximizing their efficacy.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Combination therapies. Given the chronic\u00a0nature of\u00a0obesity\u00a0requiring\u00a0prolonged treatment and the potential side effects associated with various medications, combination\u00a0therapies have been suggested as a more practical approach. This involves using lower doses of\u00a02 medications, allowing 1 drug to offset the potential\u00a0side effects of the other\u00a0while maximizing their efficacy."}
{"id": "article-120320_55", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination", "content": "In 2012, the FDA approved the combination of phentermine-topiramate for adults with a BMI of 30 kg/m\u00b2\u00a0or greater or with a BMI of 27 kg/m\u00b2 or less with at least\u00a01 weight-related comorbidity (eg, hypertension, diabetes, dyslipidemia)\u00a0to be used alongside reduced dietary caloric intake for weight loss. It is not\u00a0advisable for patients with a high cardiovascular risk due to a potential increase in heart rate; however, a 2-year trial\u00a0did not show an elevated\u00a0mortality compared to the placebo group. Long-term data on mortality is currently\u00a0unavailable.\u00a0This combination\u00a0can be\u00a0considered as the\u00a0initial option in obesity treatment, especially for\u00a0patients who did not tolerate or failed liraglutide or orlistat, particularly those with binge eating disorder.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination. In 2012, the FDA approved the combination of phentermine-topiramate for adults with a BMI of 30 kg/m\u00b2\u00a0or greater or with a BMI of 27 kg/m\u00b2 or less with at least\u00a01 weight-related comorbidity (eg, hypertension, diabetes, dyslipidemia)\u00a0to be used alongside reduced dietary caloric intake for weight loss. It is not\u00a0advisable for patients with a high cardiovascular risk due to a potential increase in heart rate; however, a 2-year trial\u00a0did not show an elevated\u00a0mortality compared to the placebo group. Long-term data on mortality is currently\u00a0unavailable.\u00a0This combination\u00a0can be\u00a0considered as the\u00a0initial option in obesity treatment, especially for\u00a0patients who did not tolerate or failed liraglutide or orlistat, particularly those with binge eating disorder."}
{"id": "article-120320_56", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination", "content": "In the Conquer trial involving 2487 patients, there was a change in body weight of -1.4 kg in the placebo group versus -8.1 in the phentermine-topiramate (7.5/46 mg) group after 56 weeks. [38] In\u00a0the extension study (Sequel) that followed patients for\u00a0an additional 52 weeks,\u00a0patients\u00a0on the low dose of phentermine-topiramate achieved a mean weight loss of 9.6 kg versus 2.1 kg in the placebo group after 108 weeks from the original baseline. [39] Although the weight loss in the second year was less pronounced,\u00a0most participants could maintain their weight loss,\u00a0while the placebo group\u00a0experienced a slight increase in body weight.\u00a0Notably, all\u00a0individuals were simultaneously participating in a lifestyle modification program.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination. In the Conquer trial involving 2487 patients, there was a change in body weight of -1.4 kg in the placebo group versus -8.1 in the phentermine-topiramate (7.5/46 mg) group after 56 weeks. [38] In\u00a0the extension study (Sequel) that followed patients for\u00a0an additional 52 weeks,\u00a0patients\u00a0on the low dose of phentermine-topiramate achieved a mean weight loss of 9.6 kg versus 2.1 kg in the placebo group after 108 weeks from the original baseline. [39] Although the weight loss in the second year was less pronounced,\u00a0most participants could maintain their weight loss,\u00a0while the placebo group\u00a0experienced a slight increase in body weight.\u00a0Notably, all\u00a0individuals were simultaneously participating in a lifestyle modification program."}
{"id": "article-120320_57", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination", "content": "Participants in the phentermine-topiramate group\u00a0exhibited\u00a0improved cardiovascular and metabolic variables and a lower incidence of diabetes than\u00a0the placebo group.\u00a0The combination\u00a0remained tolerated over 108 weeks, with adverse events occurring more frequently in the initial trial phase.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination. Participants in the phentermine-topiramate group\u00a0exhibited\u00a0improved cardiovascular and metabolic variables and a lower incidence of diabetes than\u00a0the placebo group.\u00a0The combination\u00a0remained tolerated over 108 weeks, with adverse events occurring more frequently in the initial trial phase."}
{"id": "article-120320_58", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination", "content": "The most commonly reported side effects of the medication\u00a0include paraesthesias, dizziness, dysgeusia, insomnia, constipation, and dry mouth. Patients in the medication-treated groups\u00a0experienced a slight reduction in blood pressure, accompanied by a slight increase in heart rate of 1.3 and 1.7 bpm for low and high doses, respectively, versus 0.4 in the placebo group. However, there were no reported adverse events related to the increase in heart rate.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination. The most commonly reported side effects of the medication\u00a0include paraesthesias, dizziness, dysgeusia, insomnia, constipation, and dry mouth. Patients in the medication-treated groups\u00a0experienced a slight reduction in blood pressure, accompanied by a slight increase in heart rate of 1.3 and 1.7 bpm for low and high doses, respectively, versus 0.4 in the placebo group. However, there were no reported adverse events related to the increase in heart rate."}
{"id": "article-120320_59", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination", "content": "Regarding psychiatric side effects, there was no increase in severe suicidal ideation or behavior among participants during the 108 weeks of observation. Reports of dose-dependent anxiety-related\u00a0adverse events were noted (3.1%, 6.5%, and 9.5% for placebo, 7.5/46 mg, and 15/92 mg arms, respectively), but they were mostly of mild severity. Dosing: There are\u00a04 different fixed drug combinations for the phentermine-topiramate combination. The starting dose is 3.75/23 mg for 14 days, which should then be increased to the recommended 7.5/46 mg dose. If, after 12 weeks of treatment, a 3% loss of baseline body weight does not occur, the recommendation is to\u00a0escalate the dose to 11.25/69 mg for another 14 days and then to 15/92 mg after that. If <5% of body weight is achieved after 12 weeks on the highest dose, the medication should be gradually discontinued to avoid withdrawal symptoms from topiramate.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination. Regarding psychiatric side effects, there was no increase in severe suicidal ideation or behavior among participants during the 108 weeks of observation. Reports of dose-dependent anxiety-related\u00a0adverse events were noted (3.1%, 6.5%, and 9.5% for placebo, 7.5/46 mg, and 15/92 mg arms, respectively), but they were mostly of mild severity. Dosing: There are\u00a04 different fixed drug combinations for the phentermine-topiramate combination. The starting dose is 3.75/23 mg for 14 days, which should then be increased to the recommended 7.5/46 mg dose. If, after 12 weeks of treatment, a 3% loss of baseline body weight does not occur, the recommendation is to\u00a0escalate the dose to 11.25/69 mg for another 14 days and then to 15/92 mg after that. If <5% of body weight is achieved after 12 weeks on the highest dose, the medication should be gradually discontinued to avoid withdrawal symptoms from topiramate."}
{"id": "article-120320_60", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination", "content": "Contraindications: The phentermine-topiramate combination is contraindicated during pregnancy due to teratogenicity, posing a risk of orofacial clefts in infants exposed to the medication during the first trimester of pregnancy.\u00a0Therefore, it is mandatory to obtain a pregnancy test before\u00a0initiating the drug in childbearing-age females and then monthly after that. Additionally, the combination should not be used in patients with hyperthyroidism or acute angle glaucoma and\u00a0is not recommended for individuals who have taken\u00a0monoamine oxidase inhibitors in the past 14 days. Caution is advised in patients with a history of kidney stones due to the increased risk related to topiramate. Recommended monitoring includes: Heart rate\u00a0assessment at every visit. Regular screening for suicidal behavior and ideation, with discontinuation of the drug if symptoms develop. Monitoring for visual disturbances, especially acute myopia, and signs of increased intraocular pressure.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination. Contraindications: The phentermine-topiramate combination is contraindicated during pregnancy due to teratogenicity, posing a risk of orofacial clefts in infants exposed to the medication during the first trimester of pregnancy.\u00a0Therefore, it is mandatory to obtain a pregnancy test before\u00a0initiating the drug in childbearing-age females and then monthly after that. Additionally, the combination should not be used in patients with hyperthyroidism or acute angle glaucoma and\u00a0is not recommended for individuals who have taken\u00a0monoamine oxidase inhibitors in the past 14 days. Caution is advised in patients with a history of kidney stones due to the increased risk related to topiramate. Recommended monitoring includes: Heart rate\u00a0assessment at every visit. Regular screening for suicidal behavior and ideation, with discontinuation of the drug if symptoms develop. Monitoring for visual disturbances, especially acute myopia, and signs of increased intraocular pressure."}
{"id": "article-120320_61", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination", "content": "Evaluation of cognitive\u00a0function\u00a0due to potential disturbances in attention or memory caused by\u00a0topiramate. Periodic checks of electrolytes\u00a0and\u00a0creatinine before and during treatment,\u00a0as topiramate inhibits carbonic anhydrase enzyme, predisposing\u00a0individuals to acidosis, although significant acidosis has not been reported in the trials.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination. Evaluation of cognitive\u00a0function\u00a0due to potential disturbances in attention or memory caused by\u00a0topiramate. Periodic checks of electrolytes\u00a0and\u00a0creatinine before and during treatment,\u00a0as topiramate inhibits carbonic anhydrase enzyme, predisposing\u00a0individuals to acidosis, although significant acidosis has not been reported in the trials."}
{"id": "article-120320_62", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination", "content": "Phentermine can also serve as a monotherapy in the short-term treatment of obesity. It is FDA-approved\u00a0for use over a few weeks, coupled with\u00a0exercise, behavioral modification, and caloric restriction, specifically for patients with a BMI of 30 kg/m or greater or 27 kg/m2 or less in the presence of additional risk factors, such as controlled hypertension, diabetes, hyperlipidemia.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination. Phentermine can also serve as a monotherapy in the short-term treatment of obesity. It is FDA-approved\u00a0for use over a few weeks, coupled with\u00a0exercise, behavioral modification, and caloric restriction, specifically for patients with a BMI of 30 kg/m or greater or 27 kg/m2 or less in the presence of additional risk factors, such as controlled hypertension, diabetes, hyperlipidemia."}
{"id": "article-120320_63", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination", "content": "Phentermine suppresses appetite and induces early satiety, commonly prescribed as monotherapy. A notable study, conducted in 1968 over 36 weeks, assessed continuous and intermittent administration of phentermine,\u00a0resulting in more significant weight loss than the\u00a0placebo (-12.2 and -13.0 kg for continuous and intermittent use, respectively, versus -4.8 kg in the placebo group). [40]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination. Phentermine suppresses appetite and induces early satiety, commonly prescribed as monotherapy. A notable study, conducted in 1968 over 36 weeks, assessed continuous and intermittent administration of phentermine,\u00a0resulting in more significant weight loss than the\u00a0placebo (-12.2 and -13.0 kg for continuous and intermittent use, respectively, versus -4.8 kg in the placebo group). [40]"}
{"id": "article-120320_64", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination", "content": "In the category of sympathomimetic drugs, sibutramine was withdrawn from the US and European markets in 2010\u00a0following the SCOUT study, which revealed a 16%\u00a0rise in the incidence of cardiovascular events (comprising nonfatal heart attack, nonfatal stroke, resuscitation after cardiac arrest, and cardiovascular death)\u00a0among patients\u00a0treated with the drug\u00a0compared to the\u00a0placebo group (more details on section \"issues of concern\").", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Phentermine-topiramate combination. In the category of sympathomimetic drugs, sibutramine was withdrawn from the US and European markets in 2010\u00a0following the SCOUT study, which revealed a 16%\u00a0rise in the incidence of cardiovascular events (comprising nonfatal heart attack, nonfatal stroke, resuscitation after cardiac arrest, and cardiovascular death)\u00a0among patients\u00a0treated with the drug\u00a0compared to the\u00a0placebo group (more details on section \"issues of concern\")."}
{"id": "article-120320_65", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion", "content": "Although no head-to-head studies comparing this combination therapy and phentermine-topiramate are available,\u00a0the outcomes from\u00a0published trials suggest its lower efficacy compared to the previously mentioned treatment. Consequently,\u00a0it is not recommended as the primary pharmacologic therapy for managing obesity.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion. Although no head-to-head studies comparing this combination therapy and phentermine-topiramate are available,\u00a0the outcomes from\u00a0published trials suggest its lower efficacy compared to the previously mentioned treatment. Consequently,\u00a0it is not recommended as the primary pharmacologic therapy for managing obesity."}
{"id": "article-120320_66", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion", "content": "The naltrexone-bupropion combination\u00a0serves as a\u00a0viable option, particularly beneficial for individuals aiming to quit\u00a0smoking while addressing\u00a0weight concerns. Although this combination's precise weight loss mechanism is not fully understood, it is theorized that they\u00a0synergistically impact hunger centers in the hypothalamus and the mesolimbic dopamine circuit.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion. The naltrexone-bupropion combination\u00a0serves as a\u00a0viable option, particularly beneficial for individuals aiming to quit\u00a0smoking while addressing\u00a0weight concerns. Although this combination's precise weight loss mechanism is not fully understood, it is theorized that they\u00a0synergistically impact hunger centers in the hypothalamus and the mesolimbic dopamine circuit."}
{"id": "article-120320_67", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion", "content": "Bupropion, functioning as a weak dopamine and norepinephrine reuptake inhibitor, stimulates pro-opiomelanocortin (POMC) production and the release of alpha-MSH and beta-endorphin,\u00a0an endogenous opioid, in vitro. Alpha-MSH activates the\u00a0melanocortin-4 receptor (MC4R),\u00a0contributing to reduced food intake,\u00a0increased energy expenditure, and subsequent weight loss. However,\u00a0with\u00a0sustained bupropion intake,\u00a0beta-endorphin's\u00a0down-regulatory effect on POMC cells is initiated through binding to the inhibitory mu-opioid receptor.\u00a0Naltrexone, an opioid antagonist, counteracts this effect by blocking the\u00a0mu-opioid receptor, disrupting the beta-endorphins inhibitory feedback on POMC cells. [41] [42]", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion. Bupropion, functioning as a weak dopamine and norepinephrine reuptake inhibitor, stimulates pro-opiomelanocortin (POMC) production and the release of alpha-MSH and beta-endorphin,\u00a0an endogenous opioid, in vitro. Alpha-MSH activates the\u00a0melanocortin-4 receptor (MC4R),\u00a0contributing to reduced food intake,\u00a0increased energy expenditure, and subsequent weight loss. However,\u00a0with\u00a0sustained bupropion intake,\u00a0beta-endorphin's\u00a0down-regulatory effect on POMC cells is initiated through binding to the inhibitory mu-opioid receptor.\u00a0Naltrexone, an opioid antagonist, counteracts this effect by blocking the\u00a0mu-opioid receptor, disrupting the beta-endorphins inhibitory feedback on POMC cells. [41] [42]"}
{"id": "article-120320_68", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion", "content": "FDA approved the\u00a0combination\u00a0drug in September 2014\u00a0for weight loss, diet, and exercise for patients with a BMI of 30 kg/m or greater or 27 kg/m or less\u00a0with\u00a0at least\u00a01 weight-related comorbidity. This medication offers a valuable option for individuals struggling with obesity, particularly those seeking a comprehensive approach to weight management.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion. FDA approved the\u00a0combination\u00a0drug in September 2014\u00a0for weight loss, diet, and exercise for patients with a BMI of 30 kg/m or greater or 27 kg/m or less\u00a0with\u00a0at least\u00a01 weight-related comorbidity. This medication offers a valuable option for individuals struggling with obesity, particularly those seeking a comprehensive approach to weight management."}
{"id": "article-120320_69", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion", "content": "In a multicenter randomized trial, the combination\u00a0resulted in a -6.1% reduction in body weight versus -1.3% in the placebo group, with only 50% of participants completing the 56 weeks of treatment. While\u00a0mean weight loss was greater with combination therapy than with placebo, there were significant increases in mean blood pressure and heart rate reductions in the placebo group (-2.1/2.8 versus 0.2/-0.4 mmHg and -0.1 versus 1.5 beats per minute).", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion. In a multicenter randomized trial, the combination\u00a0resulted in a -6.1% reduction in body weight versus -1.3% in the placebo group, with only 50% of participants completing the 56 weeks of treatment. While\u00a0mean weight loss was greater with combination therapy than with placebo, there were significant increases in mean blood pressure and heart rate reductions in the placebo group (-2.1/2.8 versus 0.2/-0.4 mmHg and -0.1 versus 1.5 beats per minute)."}
{"id": "article-120320_70", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion", "content": "The naltrexone-bupropion combination commonly causes nausea, headache, and constipation. The FDA\u00a0advises\u00a0monitoring patients for suicidal behavior and ideation, the risk of seizure due to bupropion lowering the seizure threshold, an increase in blood pressure and heart rate, hepatotoxicity observed with naltrexone exposure, and angle-closure glaucoma.", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion. The naltrexone-bupropion combination commonly causes nausea, headache, and constipation. The FDA\u00a0advises\u00a0monitoring patients for suicidal behavior and ideation, the risk of seizure due to bupropion lowering the seizure threshold, an increase in blood pressure and heart rate, hepatotoxicity observed with naltrexone exposure, and angle-closure glaucoma."}
{"id": "article-120320_71", "title": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion", "content": "Clinicians\u00a0are advised to refrain from prescribing the drug to patients\u00a0with high cardiovascular risk due to the observed increase in heart rate and blood pressure. A cardiovascular safety trial was interrupted in the initial phase due to a breach of confidentiality, but preliminary data showed reduced cardiovascular events. However, the issue remains controversial due to the lack of study completion.\u00a0The medication received approval with a warning for increased blood pressure and heart rate, but the cardiovascular risk was inconclusive. [43] Dosing: The initial dose is\u00a01 tablet daily\u00a0containing\u00a08 mg of\u00a0naltrexone and 90 mg of bupropion. If tolerated, the dose should increase to\u00a01 tablet twice daily after the first week and 2 tablets twice daily in the fourth week. Contraindications: Pregnancy Uncontrolled hypertension Seizure disorder Eating disorder Use of other bupropion-containing products Chronic opioid use Use of monoamine oxidase inhibitors in the previous 14 days", "contents": "Pharmacologic Therapy for Obesity -- Clinical Significance -- Naltrexone-bupropion. Clinicians\u00a0are advised to refrain from prescribing the drug to patients\u00a0with high cardiovascular risk due to the observed increase in heart rate and blood pressure. A cardiovascular safety trial was interrupted in the initial phase due to a breach of confidentiality, but preliminary data showed reduced cardiovascular events. However, the issue remains controversial due to the lack of study completion.\u00a0The medication received approval with a warning for increased blood pressure and heart rate, but the cardiovascular risk was inconclusive. [43] Dosing: The initial dose is\u00a01 tablet daily\u00a0containing\u00a08 mg of\u00a0naltrexone and 90 mg of bupropion. If tolerated, the dose should increase to\u00a01 tablet twice daily after the first week and 2 tablets twice daily in the fourth week. Contraindications: Pregnancy Uncontrolled hypertension Seizure disorder Eating disorder Use of other bupropion-containing products Chronic opioid use Use of monoamine oxidase inhibitors in the previous 14 days"}
{"id": "article-120320_72", "title": "Pharmacologic Therapy for Obesity -- Enhancing Healthcare Team Outcomes", "content": "To date,\u00a0several pharmacotherapy options for obesity exist, although\u00a0they are not a definitive solution to the problem.\u00a0While they have demonstrated positive outcomes in enhancing\u00a0cardiometabolic parameters, some may have undesirable side effects. Predicting individual responses and tolerance remains challenging.", "contents": "Pharmacologic Therapy for Obesity -- Enhancing Healthcare Team Outcomes. To date,\u00a0several pharmacotherapy options for obesity exist, although\u00a0they are not a definitive solution to the problem.\u00a0While they have demonstrated positive outcomes in enhancing\u00a0cardiometabolic parameters, some may have undesirable side effects. Predicting individual responses and tolerance remains challenging."}
{"id": "article-120320_73", "title": "Pharmacologic Therapy for Obesity -- Enhancing Healthcare Team Outcomes", "content": "Several\u00a0anti-obesity drugs have been withdrawn from the market due to significant side effects. Currently, the only approved drugs in the US are orlistat, liraglutide, semaglutide, phentermine-topiramate, phentermine alone, and bupropion-naloxone. Sibutramine was withdrawn more than ten years ago, and lorcaserin was removed more recently due to an increased risk of various types of cancer.", "contents": "Pharmacologic Therapy for Obesity -- Enhancing Healthcare Team Outcomes. Several\u00a0anti-obesity drugs have been withdrawn from the market due to significant side effects. Currently, the only approved drugs in the US are orlistat, liraglutide, semaglutide, phentermine-topiramate, phentermine alone, and bupropion-naloxone. Sibutramine was withdrawn more than ten years ago, and lorcaserin was removed more recently due to an increased risk of various types of cancer."}
{"id": "article-120320_74", "title": "Pharmacologic Therapy for Obesity -- Enhancing Healthcare Team Outcomes", "content": "The currently approved medications lack long-term safety studies.\u00a0Given\u00a0the lack of longer-term studies,\u00a0significant adverse effects, limited efficacy, and warnings over the safety of medicines,\u00a0healthcare practitioners\u00a0need to emphasize\u00a0that obesity is a chronic condition requiring lifelong monitoring. This should be accompanied by a low-calorie diet, regular physical activity, and the support of a multidisciplinary team, including a dietician, primary care provider, endocrinologist, and, when necessary, psychiatrist or therapist. Bariatric surgery should also\u00a0be\u00a0considered as an option for patients with refractory obesity who have\u00a0exhausted other medical therapies or who\u00a0face complications from obesity.\u00a0Evaluation by a behavioral therapist\u00a0is crucial to\u00a0rule out binge eating disorder or other compulsive disorders.", "contents": "Pharmacologic Therapy for Obesity -- Enhancing Healthcare Team Outcomes. The currently approved medications lack long-term safety studies.\u00a0Given\u00a0the lack of longer-term studies,\u00a0significant adverse effects, limited efficacy, and warnings over the safety of medicines,\u00a0healthcare practitioners\u00a0need to emphasize\u00a0that obesity is a chronic condition requiring lifelong monitoring. This should be accompanied by a low-calorie diet, regular physical activity, and the support of a multidisciplinary team, including a dietician, primary care provider, endocrinologist, and, when necessary, psychiatrist or therapist. Bariatric surgery should also\u00a0be\u00a0considered as an option for patients with refractory obesity who have\u00a0exhausted other medical therapies or who\u00a0face complications from obesity.\u00a0Evaluation by a behavioral therapist\u00a0is crucial to\u00a0rule out binge eating disorder or other compulsive disorders."}
{"id": "article-120320_75", "title": "Pharmacologic Therapy for Obesity -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Pharmacologic Therapy for Obesity -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}